These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 8873656)

  • 41. Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.
    Hiatt MD
    Cardiology; 1999; 91(4):243-9. PubMed ID: 10545680
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
    Barbash GI; White HD; Modan M; Van de Werf F
    J Am Coll Cardiol; 1993 Sep; 22(3):707-13. PubMed ID: 8354802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators.
    Berkowitz SD; Granger CB; Pieper KS; Lee KL; Gore JM; Simoons M; Armstrong PW; Topol EJ; Califf RM
    Circulation; 1997 Jun; 95(11):2508-16. PubMed ID: 9184581
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.
    Giraldez RR; Wiviott SD; Nicolau JC; Mohanavelu S; Morrow DA; Antman EM; Giugliano RP
    Drugs; 2009 Jul; 69(11):1433-43. PubMed ID: 19634922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data.
    Wilcox RG
    Am J Cardiol; 1996 Dec; 78(12A):20-3. PubMed ID: 8990407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
    Crenshaw BS; Ward SR; Granger CB; Stebbins AL; Topol EJ; Califf RM
    J Am Coll Cardiol; 1997 Aug; 30(2):406-13. PubMed ID: 9247512
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
    Barbash GI; White HD; Modan M; Diaz R; Hampton JR; Heikkila J; Kristinsson A; Moulopoulos S; Paolasso EA; Van der Werf T
    Circulation; 1993 Jan; 87(1):53-8. PubMed ID: 8419024
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
    Gillis JC; Wagstaff AJ; Goa KL
    Drugs; 1995 Jul; 50(1):102-36. PubMed ID: 7588083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Moen EK; Asher CR; Miller DP; Weaver WD; White HD; Califf RM; Topol EJ
    J Womens Health; 1997 Jun; 6(3):285-93. PubMed ID: 9201663
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial.
    Al-Khatib SM; Stebbins AL; Califf RM; Lee KL; Granger CB; White HD; Armstrong PW; Topol EJ; Ohman EM;
    Am Heart J; 2003 Mar; 145(3):515-21. PubMed ID: 12660676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
    Topol EJ; Ohman EM; Armstrong PW; Wilcox R; Skene AM; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White HD; Hochman JS; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno DJ; Califf RM
    Circulation; 2000 Oct; 102(15):1761-5. PubMed ID: 11023929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial.
    Holmes DR; Califf RM; Van de Werf F; Berger PB; Bates ER; Simoons ML; White HD; Thompson TD; Topol EJ
    Lancet; 1997 Jan; 349(9045):75-8. PubMed ID: 8996417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators.
    Newby LK; Rutsch WR; Califf RM; Simoons ML; Aylward PE; Armstrong PW; Woodlief LH; Lee KL; Topol EJ; Van de Werf F
    J Am Coll Cardiol; 1996 Jun; 27(7):1646-55. PubMed ID: 8636549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial.
    Karnash SL; Granger CB; White HD; Woodlief LH; Topol EJ; Califf RM
    J Am Coll Cardiol; 1995 Dec; 26(7):1651-6. PubMed ID: 7594099
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators.
    O'Connor CM; Meese RB; McNulty S; Lucas KD; Carney RJ; LeBoeuf RM; Maddox W; Bethea CF; Shadoff N; Trahey TF; Heinsimer JA; Burks JM; O'Donnell G; Krucoff MW; Califf RM
    Am J Cardiol; 1996 Apr; 77(10):791-7. PubMed ID: 8623729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.
    Gore JM; Granger CB; Simoons ML; Sloan MA; Weaver WD; White HD; Barbash GI; Van de Werf F; Aylward PE; Topol EJ
    Circulation; 1995 Nov; 92(10):2811-8. PubMed ID: 7586246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective.
    Heyland DK; Gafni A; Levine MA
    J Clin Epidemiol; 2000 Sep; 53(9):888-94. PubMed ID: 11004415
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.
    Kaul P; Armstrong PW; Chang WC; Naylor CD; Granger CB; Lee KL; Peterson ED; Califf RM; Topol EJ; Mark DB
    Circulation; 2004 Sep; 110(13):1754-60. PubMed ID: 15381645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk-benefit of thrombolysis.
    Simoons ML
    Cardiol Clin; 1995 Aug; 13(3):339-45. PubMed ID: 7585771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.